Published: September 17, 2026
Estimated reading time: 7 minutes
Marcella Brown had done everything right. For 20 years, she’d shown up every year for ovarian cancer screening, motivated by losing her own mother to the disease. In July 2023, her results came back normal. Three months later, she was diagnosed with Stage 4 ovarian cancer.
It’s the kind of news that would shake anyone. But Marcella’s story — one of fast-moving cancer, a hard-won remission, an ovarian cancer clinical trial close to home and a care team that never stopped fighting alongside her — is also a story about what’s possible when coordinated, compassionate care meets a patient’s own strength and faith.
Marcella, 68, lives in Louisville, Kentucky. Her mother’s ovarian cancer diagnosis 20 years earlier meant Marcella knew she was at higher risk — so she stayed vigilant, with annual screenings at a cancer center in Lexington.
“We lost my mother 20 years ago, and I knew I was at high risk,” Marcella said.
That vigilance made what happened next especially jarring. In October 2023, just months after her clear screening, Marcella started feeling generally unwell. She tested negative for COVID-19 and the flu, was treated for a cough and sent on her way. But that same afternoon, she found it increasingly hard to breathe and went to a Norton Immediate Care Center.
An abnormal electrocardiogram (heart test) there led to an urgent transfer to a Louisville emergency department, where doctors discovered a large amount of fluid around her right lung — more than four liters were drained.
“I knew when my OB/GYN walked in, it was going to be bad,” Marcella said.
She was right. Testing of that fluid found cancer cells. Her OB/GYN referred her to Justin W. Gorski, M.D., Ph.D., a gynecologic oncologist at Norton Cancer Institute, who confirmed Stage 4 ovarian cancer. A key blood marker used to track ovarian cancer, called CA-125, was more than 170 times higher than the normal upper limit.
The American Cancer Society estimates that ovarian cancer will claim the lives of around 12,450 women in 2026. Symptoms of this type of cancer often go unnoticed or dismissed as common stomach or intestinal issues. Very early stages of ovarian cancer often don’t have symptoms.
“When the cancer has advanced to a certain point, symptoms may appear,” Dr. Gorski said.
It’s a painful reminder that some forms of ovarian cancer — including the type Marcella had — can grow quickly enough to slip past screening and imaging.
“I thought I was staying ahead of this thing,” Marcella said. “I had just tested negative three months before.”
Marcella’s care team started her on chemotherapy right away, followed by surgery to remove as much of the solid tumors as possible. Dr. Gorski also preserved some tumor tissue during surgery — a decision that would matter a great deal later on.
The treatment worked. Marcella’s CA-125 level dropped dramatically, and she reached remission, meaning there was no evidence of active cancer.
“I got to ring the bell,” Marcella said, referring to the celebratory tradition at the end of active cancer treatment.
Sadly, the cancer returned about three months later. This is common for persistent recurrent ovarian cancer. Her care team began looking at next steps.
Marcella’s Norton Cancer Institute team encouraged her to seek outside opinions, and she visited MD Anderson Cancer Center in Houston, Texas, twice: once in spring 2025, which confirmed her current treatment plan was the right one, and again in September 2025, after the cancer had progressed further.
At that second visit, the MD Anderson oncologist recommended the same next step Dr. Gorski already had been considering: an ovarian cancer clinical trial. It turned out the two doctors actually had worked together on research years earlier, which gave Marcella extra confidence that her care in Louisville measured up to the best in the country.
“What Dr. Gorski was doing here in Louisville was the best course of action nationwide,” Marcella said. “That was so reassuring to have the doctors at a place like MD Anderson confirm it.”
Dr. Gorski moved quickly to find Marcella an appropriate ovarian clinical trial. Using genetic testing from the tumor tissue saved during her original surgery, he believed she’d be a strong candidate for a clinical trial he leads at Norton Cancer Institute — one testing a new type of drug for chemotherapy-resistant ovarian cancer.
It’s a therapy Dr. Gorski has studied since his own ovarian cancer research training years ago, when he focused on exactly the kind of chemo-resistant disease Marcella was facing.
Marcella enrolled in October 2025. The trial involved a pill taken five days a week, and within a month, her CA-125 levels were already trending down — a sign the treatment was working. She continued seeing Dr. Gorski every three weeks. Over the following months, her CA-125 dropped from over 800 to 70, and scans confirmed the cancer was responding to treatment. Throughout it all, the Norton Cancer Institute Resource Centers team offered additional support along the way.
Eventually, three appointments in a row showed Marcella’s CA-125 climbing again, so Dr. Gorski moved her off the trial and onto a standard chemotherapy regimen.
Then, in late April 2026, Marcella began experiencing severe dizziness. At first, her care team wondered if it was a side effect of the new chemotherapy. When the dizziness didn’t go away, Marcella’s daughter noticed something was seriously wrong with her mother’s balance and gait, and insisted on calling for emergency help.
An MRI revealed the cancer cells had spread to Marcella’s brain — a small lesion in the frontal lobe and a tumor near the back of her brain. She was transferred to the care of Norton Neuroscience Institute at Norton Brownsboro Hospital, and just two days later, surgeons successfully removed the tumor.
“It was disappointing, but the surgery went very well, and I was able to begin rehab right after,” Marcella said. “I was home in time for Mother’s Day.”
She’s since begun radiation to target every last cancer cell near where the tumors were.
Through every twist in Marcella’s journey — the initial diagnosis, the clinical trial, the emergency surgery — her care has stayed connected across specialists and facilities. That kind of coordinated, multidisciplinary care made it possible for Norton Healthcare to respond quickly at every turn, without Marcella having to navigate it alone.
Despite everything she’s been through, Marcella remains full of gratitude and quietly determined to see the bright side. She’s grateful, for instance, that she hasn’t needed any speech rehabilitation after her brain surgery.
“I know a woman whose husband has to have radiation five days a week for seven weeks,” Marcella said. “I think, ‘Hey, I don’t have to go that much, so I’m lucky.’”
Now retired, Marcella is the mother of three grown children and grandmother to eight. She spends her days with family and friends, stays active in her church and says her faith has carried her through the hardest moments.
When asked whether she’d want to know her prognosis, she simply shook her head.
“No, God’s got this. He knew the number of my days before I was born.”